Drug discovery

mRNA
#Drug development #Drug discovery #mRNA #mRNA-based vaccines

Where are the breakthroughs in mRNA drug discovery and development?

In this on demand webinar, hosted by DDW and sponsored by Elegen, learn about the breakthroughs in mRNA drug discovery and development. You will hear from Carsten Rudolph, Managing Director and CEO of Ethris, Klaas Zuideveld, CEO of Versameb, as well as Matthew Hill, Founder and CEO of Elegen. What… Read More

Webinar date:
Sponsored by Elegen
#Webinars

AAV
#AAV #Azenta Life Sciences #Drug development #Drug discovery #Gene therapy #Plasmid DNA

A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy

AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers. In this webinar, supported by Azenta Life Sciences, we’ll help you understand the AAV workflow, from upstream methods for AAV production and validation to downstream analysis of the… Read More

Webinar date:
Brought to you by Azenta Life Sciences
#Webinars

#Drug development #Drug discovery #Life science #Partnership #Pistoia Alliance

Pistoia Alliance announces Japanese R&D partnerships 

The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D, has announced a new partnership with Matador Japan KK to enable pre-competitive collaboration in the Japanese market.   The Alliance and Matador share the vision that bringing together experts from diverse backgrounds… Read More

#News

Medical research
#Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Cell and gene therapy #Drug development #Drug discovery #mRNA-based vaccines #Roundtable

Join our roundtable on drug discovery and development trends

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET. Join this free roundtable… Read More

Webinar date:
Sponsored by DNA Script
#News

#Drug discovery #Research #Research and development

Scientific SaaS platform to accelerate drug and materials development 

Revvity has launched its Signals Research Suite, a unified, cloud-native SaaS platform that drives scientific collaboration across R&D disciplines from drug discovery to specialty chemicals material development.   The new solution from Revvity Signals Software, the software and informatics arm of Revvity, is available worldwide. It integrates the… Read More

#News

Drug discovery
#Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Cell and gene therapy #Drug development #Drug discovery #mRNA-based vaccines #Roundtable

Exclusive roundtable on drug discovery and development trends

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET. Join this free roundtable… Read More

Webinar date:
Sponsored by DNA Script
#News

Drug discovery
#Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Cell and gene therapy #Drug development #Drug discovery #mRNA-based vaccines

Drug discovery and development trends – what will have most impact?

Hosted by DDW and sponsored by DNA Script, watch this free roundtable on demand to learn about the biggest opportunities for the future of drug discovery and development. Roundtable panellists include Commercial Research Scientist, Dr Mark Treherne, CEO of Elevation Oncology, Joe Ferra, and CEO of BioXcel… Read More

Webinar date:
Sponsored by DNA Script
#Webinars

AI brain partnership
#AI #Drug discovery #Innovation #Mental health #Partnership

Partnership targets hard-to-diagnose mental health conditions 

Pangaea Data has been awarded a strategic partnership by the newly established Mental Health Research for Innovation Centre (M-RIC).   Pangaea is a provider of a novel artificial intelligence (AI)-driven product for characterising patients by automatically discovering clinical signatures for 4,000 hard-to-diagnose conditions in an evolving, privacy-preserving and… Read More

#News

#AI #ALS #BenevolentAI #Drug discovery

BenevolentAI progresses drug for the potential treatment of ALS 

BenevolentAI, developers of AI that accelerates biopharma discovery, has delivered BEN-34712, its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS).  BEN-34712 is an oral, potent and selective brain penetrant RARɑ𝛃 (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug… Read More

#News

Artificial intelligence
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Benchling #Cancer research #Drug discovery #Machine learning #Rare disease

Latest eBook: AI and drug development

The latest eBook by DDW is out now. This 28-page eBook, sponsored by Benchling, examines the ways in which artificial intelligence and machine learning are expediting drug discovery efforts. Download this exclusive eBook to learn more about: The latest advancements in artificial intelligence… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Benchling #Cancer research #Drug discovery #Machine learning #Rare disease

AI and drug development: Using AI and machine learning to expedite drug discovery

This latest eBook sponsored by Benchling features insight on how artificial intelligence is helping advance drug discovery efforts. Download this exclusive eBook to learn more about: The latest advancements in artificial intelligence How machine learning is being used across cancer research Why AI is critical to solving challenges in drug… Read More

#DDW eBooks #Intelligence

Lightbulb, ideas, innovation
#AI #Animal models #Animal testing #BioInnovation Institute #Data science #Drug discovery #Drug research #Microbiome #Regulatory

New podcast: Innovate to reinvent the future of drug discovery

This is the latest episode of the free DDW narrated podcast, “Innovating now to reinvent the future of drug discovery”. It covers three articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Predictive biomarkers in the… Read More

#News

#Clinical research #Clinical trial #Drug discovery #Phase I trial

New episode of DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It was recently Clinical Trials Day and DDW have reported on the launch of a number… Read More

#News

#Clinical research #Clinical trial #Drug discovery #Phase I trial

This week in drug discovery (15-19 May)

News round-up for 15-19 May by DDW Digital Content Editor Diana Spencer. It’s Clinical Trials Day tomorrow and this week we have reported on the launch of a number of new Phase I trials. In-human studies have been initiated to test treatments for Parkinson’s disease, radioactive… Read More

#News

Medical research
#Drug discovery #Kynos Therapeutics #Phase I trial

First-in-human Phase I study of KMO inhibitor launches in UK

Scotland-based Kynos Therapeutics has launched a first-in-human Phase I trial of its kynurenine 3-monooxygenase (KMO) inhibitor KNS366. The study aims to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of KNS366 in healthy adult participants. The study is being conducted at a… Read More

#News